#VisualAbstract: Nirmatrelvir does not decrease symptom duration of COVID-19
1. In this randomized controlled trial, there was no difference in the median time to sustained alleviation of coronavirus disease ...
Tag: Nirmatrelvir
Nirmatrelvir does not decrease symptom duration in COVID-19
1. In this randomized controlled trial, there was no difference in the median time to sustained alleviation of coronavirus disease ...
COVID virologic rebound may occur in patients treated with nirmatrelvir-ritonavir
1. In this retrospective cohort study, the virologic rebound (VR) of coronavirus disease 2019 (COVID-19) occurred far more frequently in ...
Nirmatrelvir-ritonavir is effective in reducing COVID-19-related hospitalization
1. In this retrospective cohort study, nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and mortality associated with coronavirus disease 2019 ...
Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19
1. In this retrospective cohort study, treatment with nirmatrelvir plus ritonavir was associated with a reduced risk of hospitalization within ...
#VisualAbstract: Nirmatrelvir associated with improved COVID-19 outcomes in older adults
1. Older adults treated with nirmatrelvir were significantly less likely to be hospitalized for coronavirus disease 2019 (COVID-19) than those ...
Nirmatrelvir associated with improved COVID-19 outcomes in older adults
1. Older adults treated with nirmatrelvir were significantly less likely to be hospitalized for coronavirus disease 2019 (COVID-19) than those ...